Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
18
SONN Quote, Financials, Valuation and Earnings
Last price:
$1.26
Seasonality move
:
-4.65%
Day range:
$1.26 - $1.26
52-week range:
$1.08 - $19.30
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
5.35x
P/B ratio:
0.73x
Volume:
--
Avg. volume:
685.9K
1-year change:
-15.44%
Market cap:
$7.9M
Revenue:
$1M
EPS (TTM):
-$4.21
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SONN
Sonnet BioTherapeutics Holdings, Inc.
|
-- | -$0.49 | -100% | -91.25% | $20.00 |
|
DNLI
Denali Therapeutics, Inc.
|
$1.5M | -$0.77 | 559.6% | -13.28% | $32.21 |
|
EXAS
EXACT Sciences Corp.
|
$832M | $0.10 | 20.69% | -84.17% | $104.56 |
|
INSM
Insmed, Inc.
|
$191.7M | -$1.18 | 66.86% | -2.57% | $214.78 |
|
JANX
Janux Therapeutics, Inc.
|
$850K | -$0.71 | 599.64% | -80.26% | $65.12 |
|
QNCX
Quince Therapeutics, Inc.
|
-- | -$0.20 | -- | -38.95% | $7.67 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SONN
Sonnet BioTherapeutics Holdings, Inc.
|
$1.26 | $20.00 | $7.9M | -- | $0.00 | 0% | 5.35x |
|
DNLI
Denali Therapeutics, Inc.
|
$16.87 | $32.21 | $2.6B | -- | $0.00 | 0% | 6.62x |
|
EXAS
EXACT Sciences Corp.
|
$101.57 | $104.56 | $19.2B | -- | $0.00 | 0% | 6.18x |
|
INSM
Insmed, Inc.
|
$177.88 | $214.78 | $37.9B | -- | $0.00 | 0% | 75.70x |
|
JANX
Janux Therapeutics, Inc.
|
$14.25 | $65.12 | $857.1M | -- | $0.00 | 0% | 86.41x |
|
QNCX
Quince Therapeutics, Inc.
|
$3.56 | $7.67 | $198.2M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SONN
Sonnet BioTherapeutics Holdings, Inc.
|
0.43% | 4.130 | 0.16% | 3.26x |
|
DNLI
Denali Therapeutics, Inc.
|
4.58% | 1.220 | 2.09% | 9.43x |
|
EXAS
EXACT Sciences Corp.
|
50.33% | 1.709 | 24.46% | 2.24x |
|
INSM
Insmed, Inc.
|
44.07% | 2.512 | 2.43% | 4.18x |
|
JANX
Janux Therapeutics, Inc.
|
2.27% | -0.738 | 1.54% | 35.54x |
|
QNCX
Quince Therapeutics, Inc.
|
94.44% | 1.702 | 20.26% | 1.01x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SONN
Sonnet BioTherapeutics Holdings, Inc.
|
-$22.8K | -$5M | -645.52% | -669.7% | -284.94% | -$5.7M |
|
DNLI
Denali Therapeutics, Inc.
|
-$2.9M | -$137.4M | -42.48% | -44.34% | -- | -$105.9M |
|
EXAS
EXACT Sciences Corp.
|
$583.9M | $16.3M | -18.87% | -38% | 1.91% | $190M |
|
INSM
Insmed, Inc.
|
$111.4M | -$261.4M | -70.98% | -193.23% | -183.61% | -$222.2M |
|
JANX
Janux Therapeutics, Inc.
|
$9.5M | -$35.3M | -10.68% | -10.94% | -352.51% | -$12.9M |
|
QNCX
Quince Therapeutics, Inc.
|
-$36K | -$11.4M | -151.58% | -267.62% | -- | -$10M |
Sonnet BioTherapeutics Holdings, Inc. vs. Competitors
-
Which has Higher Returns SONN or DNLI?
Denali Therapeutics, Inc. has a net margin of -316.07% compared to Sonnet BioTherapeutics Holdings, Inc.'s net margin of --. Sonnet BioTherapeutics Holdings, Inc.'s return on equity of -669.7% beat Denali Therapeutics, Inc.'s return on equity of -44.34%.
Company Gross Margin Earnings Per Share Invested Capital SONNSonnet BioTherapeutics Holdings, Inc.-- -$0.80 $10.8M DNLIDenali Therapeutics, Inc.-- -$0.74 $970.6M -
What do Analysts Say About SONN or DNLI?
Sonnet BioTherapeutics Holdings, Inc. has a consensus price target of $20.00, signalling upside risk potential of 1487.3%. On the other hand Denali Therapeutics, Inc. has an analysts' consensus of $32.21 which suggests that it could grow by 90.96%. Given that Sonnet BioTherapeutics Holdings, Inc. has higher upside potential than Denali Therapeutics, Inc., analysts believe Sonnet BioTherapeutics Holdings, Inc. is more attractive than Denali Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SONNSonnet BioTherapeutics Holdings, Inc.1 0 0 DNLIDenali Therapeutics, Inc.17 0 0 -
Is SONN or DNLI More Risky?
Sonnet BioTherapeutics Holdings, Inc. has a beta of 1.478, which suggesting that the stock is 47.817% more volatile than S&P 500. In comparison Denali Therapeutics, Inc. has a beta of 1.115, suggesting its more volatile than the S&P 500 by 11.475%.
-
Which is a Better Dividend Stock SONN or DNLI?
Sonnet BioTherapeutics Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Denali Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sonnet BioTherapeutics Holdings, Inc. pays -- of its earnings as a dividend. Denali Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SONN or DNLI?
Sonnet BioTherapeutics Holdings, Inc. quarterly revenues are --, which are smaller than Denali Therapeutics, Inc. quarterly revenues of --. Sonnet BioTherapeutics Holdings, Inc.'s net income of -$5.6M is higher than Denali Therapeutics, Inc.'s net income of -$126.9M. Notably, Sonnet BioTherapeutics Holdings, Inc.'s price-to-earnings ratio is -- while Denali Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sonnet BioTherapeutics Holdings, Inc. is 5.35x versus 6.62x for Denali Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SONNSonnet BioTherapeutics Holdings, Inc.5.35x -- -- -$5.6M DNLIDenali Therapeutics, Inc.6.62x -- -- -$126.9M
-
Which has Higher Returns SONN or EXAS?
EXACT Sciences Corp. has a net margin of -316.07% compared to Sonnet BioTherapeutics Holdings, Inc.'s net margin of -2.3%. Sonnet BioTherapeutics Holdings, Inc.'s return on equity of -669.7% beat EXACT Sciences Corp.'s return on equity of -38%.
Company Gross Margin Earnings Per Share Invested Capital SONNSonnet BioTherapeutics Holdings, Inc.-- -$0.80 $10.8M EXASEXACT Sciences Corp.68.64% -$0.10 $5B -
What do Analysts Say About SONN or EXAS?
Sonnet BioTherapeutics Holdings, Inc. has a consensus price target of $20.00, signalling upside risk potential of 1487.3%. On the other hand EXACT Sciences Corp. has an analysts' consensus of $104.56 which suggests that it could grow by 2.95%. Given that Sonnet BioTherapeutics Holdings, Inc. has higher upside potential than EXACT Sciences Corp., analysts believe Sonnet BioTherapeutics Holdings, Inc. is more attractive than EXACT Sciences Corp..
Company Buy Ratings Hold Ratings Sell Ratings SONNSonnet BioTherapeutics Holdings, Inc.1 0 0 EXASEXACT Sciences Corp.3 18 0 -
Is SONN or EXAS More Risky?
Sonnet BioTherapeutics Holdings, Inc. has a beta of 1.478, which suggesting that the stock is 47.817% more volatile than S&P 500. In comparison EXACT Sciences Corp. has a beta of 1.417, suggesting its more volatile than the S&P 500 by 41.664%.
-
Which is a Better Dividend Stock SONN or EXAS?
Sonnet BioTherapeutics Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. EXACT Sciences Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sonnet BioTherapeutics Holdings, Inc. pays -- of its earnings as a dividend. EXACT Sciences Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SONN or EXAS?
Sonnet BioTherapeutics Holdings, Inc. quarterly revenues are --, which are smaller than EXACT Sciences Corp. quarterly revenues of $850.7M. Sonnet BioTherapeutics Holdings, Inc.'s net income of -$5.6M is higher than EXACT Sciences Corp.'s net income of -$19.6M. Notably, Sonnet BioTherapeutics Holdings, Inc.'s price-to-earnings ratio is -- while EXACT Sciences Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sonnet BioTherapeutics Holdings, Inc. is 5.35x versus 6.18x for EXACT Sciences Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SONNSonnet BioTherapeutics Holdings, Inc.5.35x -- -- -$5.6M EXASEXACT Sciences Corp.6.18x -- $850.7M -$19.6M
-
Which has Higher Returns SONN or INSM?
Insmed, Inc. has a net margin of -316.07% compared to Sonnet BioTherapeutics Holdings, Inc.'s net margin of -259.95%. Sonnet BioTherapeutics Holdings, Inc.'s return on equity of -669.7% beat Insmed, Inc.'s return on equity of -193.23%.
Company Gross Margin Earnings Per Share Invested Capital SONNSonnet BioTherapeutics Holdings, Inc.-- -$0.80 $10.8M INSMInsmed, Inc.78.29% -$1.75 $1.7B -
What do Analysts Say About SONN or INSM?
Sonnet BioTherapeutics Holdings, Inc. has a consensus price target of $20.00, signalling upside risk potential of 1487.3%. On the other hand Insmed, Inc. has an analysts' consensus of $214.78 which suggests that it could grow by 20.84%. Given that Sonnet BioTherapeutics Holdings, Inc. has higher upside potential than Insmed, Inc., analysts believe Sonnet BioTherapeutics Holdings, Inc. is more attractive than Insmed, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SONNSonnet BioTherapeutics Holdings, Inc.1 0 0 INSMInsmed, Inc.17 1 0 -
Is SONN or INSM More Risky?
Sonnet BioTherapeutics Holdings, Inc. has a beta of 1.478, which suggesting that the stock is 47.817% more volatile than S&P 500. In comparison Insmed, Inc. has a beta of 1.015, suggesting its more volatile than the S&P 500 by 1.49%.
-
Which is a Better Dividend Stock SONN or INSM?
Sonnet BioTherapeutics Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insmed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sonnet BioTherapeutics Holdings, Inc. pays -- of its earnings as a dividend. Insmed, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SONN or INSM?
Sonnet BioTherapeutics Holdings, Inc. quarterly revenues are --, which are smaller than Insmed, Inc. quarterly revenues of $142.3M. Sonnet BioTherapeutics Holdings, Inc.'s net income of -$5.6M is higher than Insmed, Inc.'s net income of -$370M. Notably, Sonnet BioTherapeutics Holdings, Inc.'s price-to-earnings ratio is -- while Insmed, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sonnet BioTherapeutics Holdings, Inc. is 5.35x versus 75.70x for Insmed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SONNSonnet BioTherapeutics Holdings, Inc.5.35x -- -- -$5.6M INSMInsmed, Inc.75.70x -- $142.3M -$370M
-
Which has Higher Returns SONN or JANX?
Janux Therapeutics, Inc. has a net margin of -316.07% compared to Sonnet BioTherapeutics Holdings, Inc.'s net margin of -243.13%. Sonnet BioTherapeutics Holdings, Inc.'s return on equity of -669.7% beat Janux Therapeutics, Inc.'s return on equity of -10.94%.
Company Gross Margin Earnings Per Share Invested Capital SONNSonnet BioTherapeutics Holdings, Inc.-- -$0.80 $10.8M JANXJanux Therapeutics, Inc.94.99% -$0.39 $999.2M -
What do Analysts Say About SONN or JANX?
Sonnet BioTherapeutics Holdings, Inc. has a consensus price target of $20.00, signalling upside risk potential of 1487.3%. On the other hand Janux Therapeutics, Inc. has an analysts' consensus of $65.12 which suggests that it could grow by 356.97%. Given that Sonnet BioTherapeutics Holdings, Inc. has higher upside potential than Janux Therapeutics, Inc., analysts believe Sonnet BioTherapeutics Holdings, Inc. is more attractive than Janux Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SONNSonnet BioTherapeutics Holdings, Inc.1 0 0 JANXJanux Therapeutics, Inc.15 1 0 -
Is SONN or JANX More Risky?
Sonnet BioTherapeutics Holdings, Inc. has a beta of 1.478, which suggesting that the stock is 47.817% more volatile than S&P 500. In comparison Janux Therapeutics, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock SONN or JANX?
Sonnet BioTherapeutics Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Janux Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sonnet BioTherapeutics Holdings, Inc. pays -- of its earnings as a dividend. Janux Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SONN or JANX?
Sonnet BioTherapeutics Holdings, Inc. quarterly revenues are --, which are smaller than Janux Therapeutics, Inc. quarterly revenues of $10M. Sonnet BioTherapeutics Holdings, Inc.'s net income of -$5.6M is higher than Janux Therapeutics, Inc.'s net income of -$24.3M. Notably, Sonnet BioTherapeutics Holdings, Inc.'s price-to-earnings ratio is -- while Janux Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sonnet BioTherapeutics Holdings, Inc. is 5.35x versus 86.41x for Janux Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SONNSonnet BioTherapeutics Holdings, Inc.5.35x -- -- -$5.6M JANXJanux Therapeutics, Inc.86.41x -- $10M -$24.3M
-
Which has Higher Returns SONN or QNCX?
Quince Therapeutics, Inc. has a net margin of -316.07% compared to Sonnet BioTherapeutics Holdings, Inc.'s net margin of --. Sonnet BioTherapeutics Holdings, Inc.'s return on equity of -669.7% beat Quince Therapeutics, Inc.'s return on equity of -267.62%.
Company Gross Margin Earnings Per Share Invested Capital SONNSonnet BioTherapeutics Holdings, Inc.-- -$0.80 $10.8M QNCXQuince Therapeutics, Inc.-- -$0.25 $19.1M -
What do Analysts Say About SONN or QNCX?
Sonnet BioTherapeutics Holdings, Inc. has a consensus price target of $20.00, signalling upside risk potential of 1487.3%. On the other hand Quince Therapeutics, Inc. has an analysts' consensus of $7.67 which suggests that it could grow by 115.36%. Given that Sonnet BioTherapeutics Holdings, Inc. has higher upside potential than Quince Therapeutics, Inc., analysts believe Sonnet BioTherapeutics Holdings, Inc. is more attractive than Quince Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SONNSonnet BioTherapeutics Holdings, Inc.1 0 0 QNCXQuince Therapeutics, Inc.4 0 0 -
Is SONN or QNCX More Risky?
Sonnet BioTherapeutics Holdings, Inc. has a beta of 1.478, which suggesting that the stock is 47.817% more volatile than S&P 500. In comparison Quince Therapeutics, Inc. has a beta of 1.033, suggesting its more volatile than the S&P 500 by 3.262%.
-
Which is a Better Dividend Stock SONN or QNCX?
Sonnet BioTherapeutics Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Quince Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sonnet BioTherapeutics Holdings, Inc. pays -- of its earnings as a dividend. Quince Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SONN or QNCX?
Sonnet BioTherapeutics Holdings, Inc. quarterly revenues are --, which are smaller than Quince Therapeutics, Inc. quarterly revenues of --. Sonnet BioTherapeutics Holdings, Inc.'s net income of -$5.6M is higher than Quince Therapeutics, Inc.'s net income of -$13.4M. Notably, Sonnet BioTherapeutics Holdings, Inc.'s price-to-earnings ratio is -- while Quince Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sonnet BioTherapeutics Holdings, Inc. is 5.35x versus -- for Quince Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SONNSonnet BioTherapeutics Holdings, Inc.5.35x -- -- -$5.6M QNCXQuince Therapeutics, Inc.-- -- -- -$13.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
72
GLTO alert for Dec 27
Galecto, Inc. [GLTO] is up 16.92% over the past day.
Sell
20
SMX alert for Dec 27
SMX (Security Matters) Plc [SMX] is down 15.76% over the past day.
Sell
11
CDNAF alert for Dec 27
Canadian Tire Corp. Ltd. [CDNAF] is down 10% over the past day.
